|
業務類別
|
Biotechnology |
|
業務概覽
|
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. |
| 公司地址
| 1050 Waltham Street, Suite 302, Lexington, MA, USA, 02421 |
| 電話號碼
| +1 617 314-6297 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.kerostx.com |
| 員工數量
| 78 |
| Dr. Lorena Lerner, PhD |
Chief Scientific Officer |
-- |
22/04/2026 |
| Ms. Esther Cho |
Chief Legal Officer |
美元 459.19K |
22/04/2026 |
| Mr. Keith Regnante |
Chief Financial Officer and Principal Accounting Officer |
美元 470.38K |
22/04/2026 |
| Dr. Jasbir Seehra, PhD |
Chief Executive Officer, President and Chairman of the Board |
美元 700.00K |
26/02/2026 |
|
|
| Mr. Charles W. Newton |
Independent Director |
22/04/2026 |
| Dr. Mary Ann Gray,PhD |
Independent Director |
22/04/2026 |
| Dr. Alpna Seth, PhD |
Independent Director |
22/04/2026 |
| Dr. Jasbir Seehra, PhD |
Chief Executive Officer, President and Chairman of the Board |
26/02/2026 |
| Mr. Jean-Jacques Bienaime |
Chairman of the Board |
22/04/2026 |
| Mr. Nima Farzan |
Independent Director |
22/04/2026 |
| Mr. Julius Knowles |
Independent Director |
22/04/2026 |
| Mr. Charles Newton |
Director |
26/02/2026 |
|
|
|
|
